XLO 8-K 2026-11-10

Xilio Therapeutics, Inc. (XLO) 8-K dated 2026-11-10 — accession 0001193125-26-454449.

Xilio Therapeutics, Inc. (XLO) is a biotechnology company listed on NASDAQ.

XLO: Xilio Therapeutics Reports Third Quarter 2026 Financial Results and Pro…

This 8-K covers: Results of operations (Item 2.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported XLO revenue for 2025-12-31 was $43.8M. Net income was -$35.0M. Revenue was up 589.9% from 2024-12-31 to 2025-12-31. XLO currently screens at market cap $55.3M.

Not investment advice. The XLO SEC hub lists recent forms. The stock page is the research view.